Content area
Full text
About the Authors:
Madhav Thambisetty
* E-mail: [email protected]
Affiliation: Laboratory of Behavioral Neuroscience, National Institute on Aging, National Institutes of Health, Baltimore, Maryland, United States of America
Andrew Simmons
Affiliation: King's College London, Institute of Psychiatry, London, United Kingdom
Abdul Hye
Affiliation: King's College London, Institute of Psychiatry, London, United Kingdom
James Campbell
Affiliation: Proteome Sciences plc, Coveham House, Cobham, United Kingdom
Eric Westman
Affiliation: King's College London, Institute of Psychiatry, London, United Kingdom
Yi Zhang
Affiliation: Department of Clinical Science, Intervention and Technology, Division of Radiology, Karolinska Institutet, Stockholm, Sweden
Lars-Olof Wahlund
Affiliation: Department of Neurobiology, Care Sciences and Society, Section of Clinical Geriatrics, Karolinska Institutet, Stockholm, Sweden
Anna Kinsey
Affiliation: King's College London, Institute of Psychiatry, London, United Kingdom
Mirsada Causevic
Affiliation: King's College London, Institute of Psychiatry, London, United Kingdom
Richard Killick
Affiliation: King's College London, Institute of Psychiatry, London, United Kingdom
Iwona Kloszewska
Affiliation: Department of Old Age Psychiatry and Psychotic Disorders, Medical University of Lodz, Lodz, Poland
Patrizia Mecocci
Affiliation: Section of Gerontology and Geriatrics, Department of Clinical and Experimental Medicine, University of Perugia, Perugia, Italy
Hilkka Soininen
Affiliation: Department of Neurology, University of Eastern Finland and University Hospital, Kuopio, Finland
Magda Tsolaki
Affiliation: Department of Neurology, Aristotle University of Thessaloniki, Thessaloniki, Greece
Bruno Vellas
Affiliation: Department of Internal and Geriatrics Medicine, Hôpitaux de Toulouse, Toulouse, France
Christian Spenger
Affiliation: Department of Clinical Science, Intervention and Technology, Division of Radiology, Karolinska Institutet, Stockholm, Sweden
Simon Lovestone
Affiliation: Laboratory of Behavioral Neuroscience, National Institute on Aging, National Institutes of Health, Baltimore, Maryland, United States of America
for the AddNeuroMed consortium
Introduction
There is an urgent need for biomarkers of Alzheimer's disease (AD); especially to detect the early stages of disease. Such biomarkers have considerable potential in both clinical practice and research where they may accelerate the development of novel disease-modifying treatments [1]. In both the United States and Europe public/private consortia are conducting trials to discover such biomarkers [2], [3]. Strategies for biomarker discovery in AD are well advanced using neuroimaging and assays of candidate proteins in cerebrospinal fluid (CSF). However these methods may not be widely available for use in large, community based, multicentre studies or in the routine clinical care of large numbers of frail elderly people.
Approaches to...